Core Viewpoint - Globus Medical, Inc. has expanded its Excelsius™ navigation capabilities with the introduction of the DuraPro™ oscillating system, aimed at enhancing procedural workflows through improved safety and efficiency [1][5]. Group 1: Product Innovation - The DuraPro™ system is designed to revolutionize the $550 million high-speed drill market with next-generation oscillation technology [2]. - DuraPro™ helps prevent soft tissue wrapping while providing a natural sensation similar to conventional spinning drills, allowing for efficient and accurate bone removal [3]. - The system features anti-skiving pilot hole drilling, maintaining drill tip trajectories and facilitating thorough discectomies [3]. Group 2: Integration and Workflow Enhancement - DuraPro™ integrates seamlessly with ExcelsiusGPS™ and ExcelsiusHub™, supporting accuracy and efficiency in both navigated and non-navigated workflows [3]. - The newly launched Verzera™ system, also integrated with ExcelsiusGPS and ExcelsiusHub, enhances existing workflows for surgeons by allowing navigation during bone removal procedures [4]. Group 3: Commitment to Clinical Needs - The expanded Power Portfolio reflects Globus Medical's commitment to addressing unmet clinical needs and providing surgeons with enhanced confidence through integrated technology [5].

Core Insights - Shares of Globus Medical (NYSE: GMED) have experienced a significant decline this year following a weak performance in the first quarter [1] - The decline was somewhat anticipated, as caution was advised in February after the company's announcement [1] Company Performance - The first quarter performance of Globus Medical was described as soft, contributing to the stock's downturn [1] - The company is under scrutiny for its financial results and market position following the disappointing earnings report [1] Investment Opportunities - The investing group "Value In Corporate Events" focuses on identifying actionable investment opportunities related to major corporate events such as earnings reports, M&A, and IPOs [1] - The group aims to provide coverage of 10 major events monthly to find the best investment opportunities [1]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Globus Medical reported financial results for Q1 2025, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06, and revenue of $598.12 million, which was $27.78 million below expectations and represented a 1.4% year-over-year decline [3] - Following the disappointing financial results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3] Financial Performance - Non-GAAP earnings per share for Q1 2025 were reported at $0.68, missing estimates by $0.06 [3] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and showing a 1.4% decline compared to the previous year [3] - The decline in performance was attributed to softer deal closures, supply chain disruptions, and timing issues with international distributor orders [3] Stock Market Reaction - The stock price of Globus Medical experienced a significant drop of $16.64 per share, equating to a 22.96% decrease [3] - The closing price after the drop was $55.82 per share on May 9, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, which was $0.06 below consensus estimates [3]. - The company's revenue for Q1 2025 was $598.12 million, missing consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders, as stated by the President and CEO of Globus [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [3] - The company reported revenue of $598.12 million, which was $27.78 million below consensus estimates and represented a 1.4% year-over-year decline [3] - Following the financial results announcement, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [3] Company Challenges - The decline in financial performance was attributed to softer Enabling Technology deal closures, temporary integration-related supply chain disruptions, and the timing of international distributor orders [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, which was $0.06 below consensus estimates [3]. - The company's revenue for Q1 2025 was $598.12 million, missing consensus estimates by $27.78 million and reflecting a 1.4% decline year-over-year [3]. - Following the announcement of these results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to softer deal closures in Enabling Technology, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported Q1 2025 financial results, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [2] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [2] - The decline in performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [2] Market Reaction - Following the financial results announcement, Globus's stock price dropped by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. following disappointing financial results for Q1 2025, which led to a significant drop in the company's stock price [1][3]. Financial Performance - Globus Medical reported non-GAAP earnings per share of $0.68 for Q1 2025, missing consensus estimates by $0.06 [3]. - The company's revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price decreased by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to several factors, including softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].

Core Viewpoint - Globus Medical, Inc. has authorized a share repurchase program of up to $500 million to address the disconnect between its intrinsic value and market valuation, reflecting confidence in its long-term growth and profitability [1][2]. Group 1: Share Repurchase Program - The share repurchase program is aimed at buying back up to $500 million of the company's outstanding common stock [1]. - The timing and number of shares repurchased will be at management's discretion, influenced by market conditions and other factors [2]. - The program will be funded using the company's cash reserves and aligns with its long-term capital allocation strategy [3]. Group 2: Company Overview - Globus Medical is a leading global musculoskeletal solutions company focused on addressing unmet clinical needs and improving patient outcomes [4]. - The company emphasizes innovation, education, and clinical support across various areas including spine, orthopedic trauma, and joint reconstruction [4].

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq. Admitted CA, NY and TX Bars lesley@portnoylaw.com 310-692-8883 www.portnoylaw.com Attorney Advertising On May 8, 2025, Globus issued a press release announcing its financial results for the first quarter of 2025. The Company reported non-G ...